Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > L2... Huge numbers on the Bid site

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Apr 19, 2021 9:29am

122 Views

Post# 33021051

RE:L2... Huge numbers on the Bid site

whisky11 wrote:

Level II Quotes

Orders

Shares

Bid

Ask

Shares

Orders

17

275,000

0.055

0.055

810,000

16

28

2,311,000

0.05

0.06

1,321,000

23

27

5,379,000

0.045

0.065

1,129,000

13

19

2,699,000

0.04

0.07

1,447,000

15

7

1,248,000

0.035

0.075

1,338,000

24